FDA Drug Market Exclusivity Periods: Time for a Change?
Monopoly periods for brand-name prescription drug markets are usually defined by patents and regulatory exclusivity earned at the time of FDA approval.
Diagnosis & Disease Information
Change in Generic Drug Prices Linked to Market Competition
The study noted a price change of -31.7% for quadropoly and 47.4% for monopoly.
Significant Number of Seniors Don’t Seek Help for Drug Costs
Among the respondents who said their medication costs were a burden, 49% had not talked to their doctors about the issue.
Former Pharma Representatives Being Used by Health Insurers to Lower Costs
Former pharma reps are educating doctors about costs of medications and encouraging the use of generic drugs.
AMA Strives to Improve Drug Pricing Transparency
At the annual meeting, the physicians’ group adopted new policies on drug pricing to protect patients.
Soaring Costs of Prescriptions for Elderly Continue
The cost of brand-name drugs for chronic conditions rose nearly 130 times faster than the inflation rate.
Outcomes-Based Pricing Suggested for Expensive, Novel Drugs
Strategy would encourage manufacturers and insurers to share accountability for clinical outcomes
- Loading...
Loading...
Loading... 
Loading...